Also listed under Autoimmune Diseases
ClinicalTrials.gov term: Lupus Erythematosus, Systemic
Lupus (SLE) clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-17
What changed in the last 30 days
42 trials changed in the last 30 days: 1 stopped, 17 with notable changes, 24 with minor changes only.
- Minor: SOLUNA · Mosunetuzumab · Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Primary completion pushed from Feb 28, 2028 to Aug 11, 2028
- Minor: Centrally Acting ACE Inhibition in SLE Trial completed
- Notable: ALLEGORY · Obinutuzumab · Systemic Lupus Erythematosus Results posted: Nov 12, 2026
- Notable: CD19/CD22/BCMA CAR-T Cells (BZE2204) · Relapsed or Refractory Autoimmune Diseases Primary endpoint(s) modified
- Minor: GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants Enrollment closed, study ongoing
- Notable: (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Recruitment opened
- Minor: ROSY-S · Rollover Study · Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment Trial sites expanded: 153 → 166 locations
- Stopped: KP104 · Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus Withdrawn before enrolling
- Minor: SIRIUS-SLE LTE · Ianalumab · Systemic Lupus Erythematosus (SIRIUS-SLE Extension) Trial sites expanded: 162 → 167 locations
-
Minor: 4 trials marked Unknown by the registry's verification sweep Changed
- Minor: BAH242 · Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Minor: RAISE · Rare AutoImmune SElf-management Programme Development Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable: Dapa-Active LN · Dapagliflozin in Active Lupus Nephritis Primary completion moved earlier from Jul 2029 to Jul 1, 2028
- Notable: Healthy Adult Participants and · Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body Primary endpoint(s) modified
- Minor: Cevostamab · Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Trial sites expanded: 1 → 11 locations
- Notable: MYTP01 for Immune-Mediated Diseases Start date pushed from Oct 2026 to Dec 2026
- Minor: Enpatoran · Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) Trial sites expanded: 57 → 70 locations
- Minor: ELOWEN-1 · Enpatoran · Cutaneous Manifestations of Lupus With or Without Systemic Disease Trial sites expanded: 60 → 74 locations
- Notable: Pain Phenotyping of Rheumatic Diseases - An Observational Study Recruitment opened
- Minor: GARDENIA-SLE · Nipocalimab · Moderate to Severe Systemic Lupus Erythematosus Trial sites expanded: 260 → 272 locations
- Minor: AERIS · VENT-03 · Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus Enrollment closed, study ongoing
- Minor: MIL62 in Systemic Lupus Erythematosus Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-12 | NCT07931170 Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study | Pediatric Nephrology Research Consortium new | |
| 2026-11-10 | NCT07930091 Molecular Biomarkers for Discriminating Lupus Nephritis in SLE | Egyptian Chinese University new | |
| 2026-11-03 | NCT07913919 Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | University of Cambridge new | |
| 2026-10-30 | NCT07906145 A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD new | Phase 1 |
| 2026-10-29 | NCT07902622 Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus | Foundation University Islamabad new | |
| 2026-10-28 | NCT07901764 MYTP01 for Immune-Mediated Diseases | Zhejiang Provincial People's Hospital new | |
| 2026-10-28 | NCT07901634 Association of Inflammatory Biomarkers and Ferritin With Severity of Pediatric Systemic… | Desy Wulandari new | |
| 2026-10-23 | NCT07892651 MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) | Axiom Bioregistry new | |
| 2026-10-09 | NCT07868289 Effectiveness of Resonance Frequency Breathing Exercises in Patients With Systemic Lupus… | Istanbul University - Cerrahpasa new | |
| 2026-09-28 | NCT07844200 The Primary Objective of the Trial is to Evaluate the Effect of the Addition of… | Medical Association for the Study of Cancer Biology and Treatment new | Phase 2 |
Active trials by phase
| Early Phase 1 | 39 | |
| Phase 1 | 117 | |
| Phase 1/2 | 45 | |
| Phase 2 | 62 | |
| Phase 2/3 | 5 | |
| Phase 3 | 41 | |
| Phase 4 | 20 |
Not charted: 225 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Assiut University (26) · AstraZeneca (26) · The Children's Hospital of Zhejiang University School of Medicine (11) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (11) · Novartis Pharmaceuticals (9) · Assistance Publique - Hôpitaux de Paris (7) · Bristol-Myers Squibb (7) · Chinese SLE Treatment And Research Group (7) · Sohag University (7) · Beijing GoBroad Hospital (6)
Get alerts when Lupus (SLE) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.